ロード中...
Osimertinib in patients with epidermal growth factor receptor T790M advanced non‐small cell lung cancer selected using cytology samples
Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR‑TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertini...
保存先:
| 出版年: | Cancer Sci |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5891183/ https://ncbi.nlm.nih.gov/pubmed/29363250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13511 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|